Enhancing Solubility and Bioavailability of Rosuvastatin into Self Nanoemulsifying Drug Delivery System

Basit Öğe Kaydı
dc.contributor.authorKarasulu, Hatice Yasim
dc.contributor.authorGundogdu, Evren
dc.contributor.authorTurk, Ugur Onsel
dc.contributor.authorTurgay, Tugce
dc.contributor.authorApaydin, Sebnem
dc.contributor.authorSimsir, Ilgin Yildirim
dc.contributor.authorYilmaz, Condeger
dc.contributor.authorKarasulu, Ercument
dc.date.accessioned2019-10-27T10:45:16Z
dc.date.available2019-10-27T10:45:16Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to develop new Rosuvastatin calcium (RCa) self nanoemulsifying drug delivery system (SNEDDS) and to evaluate the bioavailability and pharmacodynamic effect of RCa-SNEDDS in Yorkshire pigs. Methods: Firstly, SNEDDS was developed and prepared then RCa was incorporated into SNEDDS which was evaluated regarding their characterization, stability properties, drug release profiles, permeation and cytotoxicity studies. Finally, in vivo performance of RCa-SNEDDS (F1-RCa-SNEDDS) was examined by pharmacokinetic and pharmacodynamics studies. The average droplet size of RCa-SNEDDS ranged between 200 and 250 nm. RCa-SNEDDS that contained 12.8% Oleic acid, 11 % Labrafil M, 3.3 % Labrasol and 4.4 % Transcutol HP were found to be stable and exhibited approximately 4-fold higher permeation than commercial tablet (Crestor (R) 20 mg tablet). Results: In pharmacokinetic studies, when F1 -RCa-SNEDDS and commercial tablet were administered orally, F1-RCa-SNEDDS showed higher bioavailability of RCa than commercial tablet. Respectively, in pharmacodynamic studies, triglyceride and total cholesterol levels were significantly reduced with F1-RCa-SNEDDS formulation by 37% and 19% when compared to baseline values. Conclusion: However, these decreases with commercial formulation were only 6% and 2% respectively. According to these findings, development formulation could be potentially used to enhance the oral absorption of RCa.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (Tubitak)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [112S637]en_US
dc.description.sponsorshipThis study was supported by The Scientific and Technological Research Council of Turkey (Tubitak 112S637).en_US
dc.identifier.doi10.2174/1567201815666180226114545en_US
dc.identifier.endpage1082en_US
dc.identifier.issn1567-2018
dc.identifier.issn1875-5704
dc.identifier.issue7en_US
dc.identifier.pmid29484996en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1072en_US
dc.identifier.urihttps://doi.org/10.2174/1567201815666180226114545
dc.identifier.urihttps://hdl.handle.net/11454/31120
dc.identifier.volume15en_US
dc.identifier.wosWOS:000441763900016en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Drug Deliveryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRosuvastatinen_US
dc.subjectbioavailabilityen_US
dc.subjectSNEDDSen_US
dc.subjectpharmacokineticen_US
dc.subjectoral absorptionen_US
dc.subjectbaselineen_US
dc.titleEnhancing Solubility and Bioavailability of Rosuvastatin into Self Nanoemulsifying Drug Delivery Systemen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu